Cftr Trikafta denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy Before Trikafta — and How to Override It

UnitedHealthcare's (UHC) step-therapy requirement for Trikafta (elexacaftor/tezacaftor/ivacaftor) means the plan is requiring that a patient try one or more other CFTR modulators before approving the medication. This "fail first" structure is embedded in UHC's coverage policy and applied at prior-authorization review. For cystic fibrosis (CF) patients, step-therapy requirements on CFTR modulators are among the most consistently overridden denial types because they can directly conflict with the FDA-approved indication profile and with published Cystic Fibrosis Foundation care standards.

## Why This Denial Happens

Step-therapy protocols are formulary cost-management tools. They are constructed at the policy level without accounting for individual CFTR mutation profiles. Because different CFTR modulators are approved for distinct mutation classes, a step-therapy ladder that requires prior use of an earlier-generation modulator may be inapplicable if that drug is not indicated for the patient's specific mutation.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or applicable state law, file a formal appeal within the timeframe on the denial letter. Request the full text of UHC's step-therapy criteria and the specific prior steps being required.
• Step-therapy exception laws: Many states have enacted step-therapy override statutes requiring health plans to grant exceptions when the required prior drug is medically inappropriate or when the patient has already tried it. Determine whether your plan is state-regulated and cite the applicable exception standard.
• External review (ACA §2719): After exhausting the internal appeal, or concurrently in urgent cases, request independent external review within approximately four months of the final denial. Reviewers apply evidence-based standards and regularly override step-therapy denials when clinical inapplicability is documented.
• Expedited review: If delay would seriously jeopardize health, invoke the 72-hour expedited track.

## Documentation to Gather

1. Mutation confirmation — genetic testing report confirming the CFTR mutation(s) and a prescriber statement that the mutation is within Trikafta's FDA-approved indication. 2. Prior-step inapplicability analysis — a prescriber letter explaining, for each drug listed as a required prior step in UHC's policy, why that drug is not indicated for this patient's mutation class per its FDA label — or documenting prior trial, failure, and reason for discontinuation. 3. Medical-necessity letter — CF specialist attestation that Trikafta is the appropriate first choice for this patient consistent with the Cystic Fibrosis Foundation care guidelines. 4. Clinical severity documentation — recent lung function data, exacerbation history, nutritional status, and the clinical risk of delaying Trikafta to pursue a prior step. 5. CFF guideline reference — your prescriber may cite the applicable Cystic Fibrosis Foundation treatment guideline in the letter.

## Criteria-Mapping Structure

Obtain UHC's published step-therapy policy for CFTR modulators and the FDA prescribing labels for Trikafta and the required prior-step drugs. Build a direct override table:

| Required Prior Step | Why It Is Inapplicable or Already Completed | |---|---| | Each drug listed as a required step in UHC's policy | Mutation-based inapplicability per FDA label, OR documented trial/failure with dates and outcomes | | FDA indication for Trikafta | Mutation documentation confirming on-label use | | CFF guideline alignment | Reference from prescriber letter |

A mutation-based step-therapy override argument — showing that the required prior drug is not FDA-approved for this patient's mutation — is one of the most compelling and consistently successful appeal arguments available for this drug class.